NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 18 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – SS Innovations International Inc. (NASDAQ: SSII) Eyes Growing Opportunity for Surgical Robotics
SS Innovations International (NASDAQ: SSII) is building momentum for its SSi Mantra surgical robotic system,…
-
QualityStocksNewsBreaks – Silynxcom Ltd. (NYSE American: SYNX) Advances Tactical Communications with Drone Detection, Vital-Sign Monitoring
Silynxcom (NYSE American: SYNX) is expanding its in-ear tactical communication technology with features designed to…
-
Nevada Retakes the World’s Top Mining Jurisdiction Ranking, and Lahontan Gold Is Already Permitting a Mine There
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid…